Journal of Clinical Chemistry and Laboratory Medicine
Open Access

Abstract

Clinical Association of Antinuclear Antibodies (ANA) Anti-NuMA1 and Anti-NuMA2 (Anti-HsEg5) in Patients with Autoimmune and Cardiovascular Disease

Maria Elena Soto, Nidia Hernández Becerril, Genaro Reyes Ríos, Claudia Chiney, Mario Navarro, Verónica Guarner-Lans and Carlos Núñez Álvarez

Introduction: The prevalence of anti-NuMA1 and anti-NuMA2 antibodies in autoimmune, hepatic, infectious and renal inflammatory diseases is well known; however, its presence and possible relevance in cardiovascular diseases still needs to be elucidated. Aim: To evaluate the prevalence of positive anti-NuMA1 and anti-NuMA2 antibody patterns in subjects with autoimmune, non-autoimmune and/or cardiac diseases. Material and methods: This was an observational study run from January 2010 to January 2018. Individuals whose treating physician requested an antibody study and we detected anti NuMA1 and anti NuMA2 pattern in any patients. The files from these patients were reviewed to obtain general data, signs, symptoms, time of evolution of the disease, determination of specific antibodies and the established diagnoses. Results: From a total of 7163 patient files 46 had NuMA1 pattern and out of them 24 (52%) had autoimmune disease (AD): 8 rheumatoid arthritis, 10 systemic lupus erythematosus (SLE), 2 antiphospholipid syndrome, 1 polymyositis, 1 fibromyalgia, 1 primary Sjogren and 1 Devic syndrome. In 15 patients (32%), cardiovascular diseases (CVD) were diagnosed and in only one of them there was an associated autoimmune disease. In three patients, there was a positive specificity for anti-SSA antigen, RNP in addition to the anti-NuMA. Rheumatoid factor, anti B2glicoprotein was present in 1 patient. Anti NuMA1 was found in 4 patients (9%); one of which had kidney disease and 3 had cardiopulmonary disease (7%). Eleven patients were positive to anti-NuMA2, five with autoimmune diseases (46%), one with cardiovascular disease (9%), two with cardiopulmonary diseases (18%) and three with renal disease (27%). Conclusion: The prevalence of high levels of antinuclear antibodies with a NuMA1 and/or NuMA2 pattern is present in patients having cardiovascular disease without there being a coexisting autoimmune disease. This finding may indicate a specific form of autoimmunity.